ADVOCATE BROMENN MEDICAL CENTER
- Type
- Teaching hospital
- Where
- Normal, IL
- Medicare CCN
- 140127
- Received
- $1,366,446 in 292 records, 2019 ($311,355 general, $1,055,091 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 120 | $311,355 |
| 2019 | Research payment | 172 | $1,055,091 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 172 | $1,055,091 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 39 | $121,522 |
| Gift | 25 | $106,291 |
| Space rental or facility fees (teaching hospital only) | 32 | $49,950 |
| Grant | 10 | $17,976 |
| Education | 7 | $7,556 |
| Consulting Fee | 4 | $6,825 |
| Food and Beverage | 1 | $676 |
| Charitable Contribution | 2 | $557 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Stryker Corporation | $9,197 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $9,197 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $5,966 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $5,966 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $5,966 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $5,966 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $5,966 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $5,559 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $5,559 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $4,042 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $3,780 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $3,780 | Gift | In-kind items and services | NSE - HIGH SPEED DRILLS Device, NEURO SPINE ENT | 2019 | |
| 2019-12-31 | Stryker Corporation | $3,322 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $3,201 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $2,721 | Gift | In-kind items and services | SAMURAI BLADE Device, SPORTS MEDICINE | 2019 | |
| 2019-12-31 | Stryker Corporation | $2,667 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $2,667 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $2,667 | Gift | In-kind items and services | SURG - SYSTEM 7 Device, SURGICAL | 2019 | |
| 2019-12-31 | AstraZeneca UK Limited | $2,188 | Research payment | In-kind items and services | BRILINTA Drug, Cardiovascular and Metabolism | HESTIA3 Efficacy and Safety of Ticagrelor in Ped | 2019 |
| 2019-12-31 | AstraZeneca UK Limited | $1,890 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $1,234 | Research payment | In-kind items and services | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclon | 2019 | |
| 2019-12-31 | Allergan, Inc. | $804 | Research payment | Cash or cash equivalent | VIBERZI Drug, GASTROENTEROLOGY | Pediatric 12-17 Clinical PharmacologyEfficacySafety Study | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $637 | Research payment | In-kind items and services | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $483 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $360 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati | 2019 |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $347 | Research payment | In-kind items and services | MEDI8897 RSV mAb-D5290C00003 Phase 2 / 2b Clinical Trial | 2019 | |
| 2019-12-31 | Edwards Lifesciences Corporation | $184 | Education | In-kind items and services | EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $129 | Research payment | Cash or cash equivalent | MAGNETOM Aera Device, MR - MRI | AHHC2015MR100Chaptini | 2019 |
| 2019-12-31 | Edwards Lifesciences Corporation | $121 | Education | In-kind items and services | EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring | 2019 | |
| 2019-12-31 | Abbott Laboratories | $105 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-12-30 | Abbott Laboratories | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FreeStyle Libre Device, Diabetes Care | 2019 | |
| 2019-12-24 | Boston Scientific Corporation | $2,000 | Grant | Cash or cash equivalent | GENERAL - STRUCTURAL HEART Device, STRUCTURAL HEART | 2019 | |
| 2019-12-23 | ABBVIE INC. | $7,508 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-12-20 | ABBVIE INC. | $67 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-12-19 | Regeneron Pharmaceuticals, Inc. | $6,914 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients | 2019 |
| 2019-12-19 | Smith+Nephew, Inc. | $3,300 | Gift | In-kind items and services | Stravix Biological, Other Advanced Wound Management | 2019 | |
| 2019-12-19 | Smith+Nephew, Inc. | $3,300 | Gift | In-kind items and services | Stravix Biological, Other Advanced Wound Management | 2019 | |
| 2019-12-19 | Smith+Nephew, Inc. | $3,300 | Gift | In-kind items and services | Stravix Biological, Other Advanced Wound Management | 2019 | |
| 2019-12-19 | Shockwave Medical, Inc | $2,889 | Research payment | Cash or cash equivalent | Shockwave Medical Peripheral Lithoplasty System Device, Lithoplasty | Randomized study of the Shockwave Medical Peripheral Lithoplasty System used in combination with DCB versus standard bal | 2019 |
| 2019-12-19 | Smith+Nephew, Inc. | $2,200 | Gift | In-kind items and services | Stravix Biological, Other Advanced Wound Management | 2019 | |
| 2019-12-19 | Shire North American Group Inc | $1,000 | Research payment | Cash or cash equivalent | ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, PLACEBO-CONTROLLED, R | 2019 | |
| 2019-12-19 | Shire North American Group Inc | $490 | Research payment | Cash or cash equivalent | ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, PLACEBO-CONTROLLED, R | 2019 | |
| 2019-12-17 | AstraZeneca Pharmaceuticals LP | $6,366 | Research payment | Cash or cash equivalent | LYNPARZA Drug, Oncology | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati | 2019 |
| 2019-12-17 | Medical Device Business Services, Inc. | $2,976 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-13 | Janssen Pharmaceuticals, Inc | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-12-12 | CSL Behring | $3,588 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-12 | Abbott Laboratories | $2,375 | Research payment | Cash or cash equivalent | MultiPoint Pacing Device, Cardiac Arrhythmias and Heart Failure | MultiPoint Pacing Post Market Study | 2019 |
| 2019-12-12 | Abbott Laboratories | $2,000 | Education | Cash or cash equivalent | 2019 | ||
| 2019-12-10 | Amgen Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Corlanor Drug, Cardiology | 2019 | |
| 2019-12-07 | Novartis Pharmaceuticals Corporation | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | 2019 | |
| 2019-12-07 | SANOFI-AVENTIS U.S. LLC | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PRALUENT Drug, CARDIOVASCULAR | 2019 | |
| 2019-12-05 | CSL Behring | $3,318 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-05 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-12-05 | CSL Behring | $300 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-03 | Kowa Research Institute, Inc. | $5,691 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-12-02 | ABBVIE INC. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Mavyret Drug, Virology | 2019 | |
| 2019-11-27 | ABBVIE INC. | $14,370 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-11-27 | Regeneron Pharmaceuticals, Inc. | $7,093 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients | 2019 |
| 2019-11-26 | ABBVIE INC. | $3,522 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-11-26 | Boston Scientific Corporation | $2,000 | Grant | Cash or cash equivalent | GENERAL - BILIARY DEVICES Device, BILIARY DEVICES | 2019 | |
| 2019-11-22 | Smith+Nephew, Inc. | $5,910 | Gift | In-kind items and services | Stravix Biological, Other Advanced Wound Management | 2019 | |
| 2019-11-21 | Regeneron Pharmaceuticals, Inc. | $6,750 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients | 2019 |
| 2019-11-21 | Regeneron Pharmaceuticals, Inc. | $2,116 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients | 2019 |
| 2019-11-21 | Kowa Research Institute, Inc. | $66 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-11-14 | Allergan, Inc. | $1,277 | Research payment | Cash or cash equivalent | VIBERZI Drug, GASTROENTEROLOGY | Pediatric 12-17 Clinical PharmacologyEfficacySafety Study | 2019 |
| 2019-11-14 | Allergan, Inc. | $1,250 | Education | Cash or cash equivalent | 2019 | ||
| 2019-11-13 | Abbott Laboratories | $67,859 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-11-13 | ABBVIE INC. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Humira Biological, Immunology | 2019 | |
| 2019-11-08 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-11-08 | Novartis Pharmaceuticals Corporation | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | 2019 | |
| 2019-11-08 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-11-07 | CSL Behring | $1,803 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-07 | CSL Behring | $100 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-04 | Boston Scientific Corporation | $2,000 | Grant | Cash or cash equivalent | GENERAL - THERAPIES Device, THERAPIES | 2019 | |
| 2019-11-04 | Abbott Laboratories | $1,700 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-11-04 | Shockwave Medical, Inc | $945 | Research payment | Cash or cash equivalent | Shockwave Medical Peripheral Lithoplasty System Device, Lithoplasty | Randomized study of the Shockwave Medical Peripheral Lithoplasty System used in combination with DCB versus standard bal | 2019 |
| 2019-11-01 | ABBVIE INC. | $2,484 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-10-31 | Novartis Pharmaceuticals Corporation | $7,360 | Research payment | Cash or cash equivalent | LUCENTIS Drug, OPHTHALMOLOGY | RAINBOW STUDY A RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF RANIBIZUMAB COMPARED WITH LASER THERAP | 2019 |
| 2019-10-30 | Regeneron Pharmaceuticals, Inc. | $6,218 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients | 2019 |
| 2019-10-30 | Abbott Laboratories | $3,412 | Research payment | Cash or cash equivalent | CardioMEMS Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2019 |
| 2019-10-30 | ABBVIE INC. | $3,370 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-10-30 | Abbott Laboratories | $1,184 | Research payment | Cash or cash equivalent | CardioMEMS Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2019 |
| 2019-10-28 | Shockwave Medical, Inc | $8,708 | Research payment | Cash or cash equivalent | Shockwave Medical Peripheral Lithoplasty System Device, Lithoplasty | Randomized study of the Shockwave Medical Peripheral Lithoplasty System used in combination with DCB versus standard bal | 2019 |
| 2019-10-28 | Shockwave Medical, Inc | $2,700 | Research payment | Cash or cash equivalent | Shockwave Medical Peripheral Lithoplasty System Device, Lithoplasty | Randomized study of the Shockwave Medical Peripheral Lithoplasty System used in combination with DCB versus standard bal | 2019 |
| 2019-10-26 | Allergan, Inc. | $1,000 | Education | Cash or cash equivalent | 2019 | ||
| 2019-10-25 | Kowa Research Institute, Inc. | $4,408 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-10-23 | Abbott Laboratories | $14,690 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-10-18 | AstraZeneca Pharmaceuticals LP | $4,014 | Research payment | Cash or cash equivalent | EPANOVA Drug, Cardiovascular and Metabolism | A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs wi | 2019 |
| 2019-10-16 | Allergan, Inc. | $1,000 | Education | Cash or cash equivalent | 2019 | ||
| 2019-10-11 | Regeneron Pharmaceuticals, Inc. | $6,750 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients | 2019 |
| 2019-10-10 | Abbott Laboratories | $2,150 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-10-09 | STERIS CORPORATION | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Exacto Cold Snare Device, 78 Gastroenterology | 2019 | |
| 2019-10-09 | Stryker Corporation | $1,846 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $595 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $537 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $152 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $99 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $92 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $41 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $31 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-03 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-10-02 | AstraZeneca Pharmaceuticals LP | $25,560 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclon | 2019 | |
| 2019-10-02 | ABBVIE INC. | $2,999 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-10-01 | Kowa Research Institute, Inc. | $20,261 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-10-01 | CSL Behring | $1,500 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-30 | Abbott Laboratories | $175 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-09-30 | Abbott Laboratories | $175 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-09-27 | ABBVIE INC. | $2,800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Creon Drug, Endocrinology | 2019 | |
| 2019-09-27 | ABBVIE INC. | $1,413 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-09-26 | Medical Device Business Services, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LINX Reflux Management System Device, Endo-Mechanical | 2019 | |
| 2019-09-26 | Allergan, Inc. | $2,000 | Education | Cash or cash equivalent | 2019 | ||
| 2019-09-25 | ABBVIE INC. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Humira Biological, Immunology | 2019 | |
| 2019-09-24 | ABBVIE INC. | $156 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-09-19 | Wilson Cook Medical Incorporated | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-09-19 | Abbott Laboratories | $1,300 | Research payment | Cash or cash equivalent | Nanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart Failure | A safety and effectiveness trial for a leadless pacemaker system | 2019 |
| 2019-09-16 | Allergan, Inc. | $2,066 | Research payment | Cash or cash equivalent | VIBERZI Drug, GASTROENTEROLOGY | Pediatric 12-17 Clinical PharmacologyEfficacySafety Study | 2019 |
| 2019-09-16 | Sandoz Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TREPROSTINIL Drug, PULMONARY ARTERIAL HYPERTENSION | 2019 | |
| 2019-09-13 | Shockwave Medical, Inc | $2,889 | Research payment | Cash or cash equivalent | Shockwave Medical Peripheral Lithoplasty System Device, Lithoplasty | Randomized study of the Shockwave Medical Peripheral Lithoplasty System used in combination with DCB versus standard bal | 2019 |
| 2019-09-11 | VERTEX PHARMACEUTICALS INCORPORATED | $4,645 | Research payment | Cash or cash equivalent | A Study Evaluating the Long-term Safety of VX-445 Combination Therapy | 2019 | |
| 2019-09-11 | Abbott Laboratories | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cardiovascular- Research only Device, Cardiac Arrhythmias and Heart Failure | 2019 | |
| 2019-09-11 | Abbott Laboratories | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cardiovascular- Research only Device, Cardiac Arrhythmias and Heart Failure | 2019 | |
| 2019-09-06 | Shire North American Group Inc | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-09-06 | Medline Industries LP | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-09-03 | ABBVIE INC. | $1,368 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-09-03 | ABBVIE INC. | $1,350 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-09-03 | ABBVIE INC. | $624 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-09-03 | ABBVIE INC. | $270 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-08-30 | CSL Behring | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-08-29 | ABBVIE INC. | $10,733 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-08-29 | ABBVIE INC. | $1,830 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-08-22 | Smith+Nephew, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Allevyn Life Device, Exudate Management | 2019 | |
| 2019-08-21 | Medline Industries LP | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-08-21 | Boston Scientific Corporation | $1,500 | Grant | Cash or cash equivalent | GENERAL - STRUCTURAL HEART Device, STRUCTURAL HEART | 2019 | |
| 2019-08-21 | ABBVIE INC. | $900 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Creon Drug, Endocrinology | 2019 | |
| 2019-08-19 | Becton, Dickinson and Company | $750 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-08-15 | ABBVIE INC. | $312 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-08-14 | Abbott Laboratories | $66,524 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-08-08 | Janssen Pharmaceuticals, Inc | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-08-07 | Abbott Laboratories | $34,012 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-08-07 | Abbott Laboratories | $1,299 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-08-07 | Abbott Laboratories | $937 | Research payment | Cash or cash equivalent | AMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart Failure | Closure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study | 2019 |
| 2019-08-06 | ABBVIE INC. | $6,359 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-08-06 | ABBVIE INC. | $2,101 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-08-06 | ABBVIE INC. | $1,629 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-08-06 | ABBVIE INC. | $1,296 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-08-06 | ABBVIE INC. | $1,282 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-08-06 | ABBVIE INC. | $1,215 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-08-06 | ABBVIE INC. | $1,024 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-08-06 | ABBVIE INC. | $799 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-08-06 | ABBVIE INC. | $645 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-07-30 | ABBVIE INC. | $1,691 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-07-24 | Abbott Laboratories | $125 | Research payment | Cash or cash equivalent | CardioMEMS Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2019 |
| 2019-07-18 | Becton, Dickinson and Company | $99,247 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-07-18 | Abbott Laboratories | $3,000 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-07-18 | Abbott Laboratories | $1,500 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-07-18 | PUMA BIOTECHNOLOGY, INC. | $300 | Research payment | Cash or cash equivalent | Nerlynx Drug, Oncology | A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | 2019 |
| 2019-07-17 | Novartis Pharmaceuticals Corporation | $3,425 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED 8 WEEK STUDY TO EVALUATE THE EFFECT OF LCZ696 VER | 2019 |
| 2019-07-17 | Surmodics, Inc. | $1,086 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-07-16 | Stryker Corporation | $1,471 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $626 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $457 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $120 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $118 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $83 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $51 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $35 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-15 | ABBVIE INC. | $13,772 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-07-12 | Kowa Research Institute, Inc. | $99 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-07-04 | Abbott Laboratories | $37,899 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-06-30 | Abbott Laboratories | $70 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-06-27 | ABBVIE INC. | $234 | Research payment | Cash or cash equivalent | Creon Drug, Endocrinology | P12-792 | 2019 |
| 2019-06-26 | Surmodics, Inc. | $1,350 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-06-26 | Surmodics, Inc. | $519 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-06-26 | ABBVIE INC. | $156 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-06-25 | ABBVIE INC. | $312 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-06-21 | Kowa Research Institute, Inc. | $66 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-06-20 | Abbott Laboratories | $4,000 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-06-19 | Abbott Laboratories | $18,029 | Research payment | Cash or cash equivalent | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-06-13 | CSL Behring | $13,489 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-06-13 | Kowa Research Institute, Inc. | $7,816 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-06-13 | CSL Behring | $2,500 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-06-07 | Abbott Laboratories | $2,475 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-06-06 | Merck Sharp & Dohme LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | GARDASIL Biological, VACCINE | 2019 | |
| 2019-06-03 | AstraZeneca UK Limited | $25,212 | Research payment | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | HESTIA3 Efficacy and Safety of Ticagrelor in Ped | 2019 |
| 2019-06-03 | Abbott Laboratories | $3,037 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Alinity m Device, Diagnostics | 2019 | |
| 2019-06-03 | Abbott Laboratories | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Alinity m Device, Diagnostics | 2019 | |
| 2019-06-03 | Abbott Laboratories | $1,853 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Alinity m Device, Diagnostics | 2019 | |
| 2019-06-03 | Abbott Laboratories | $708 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Alinity m Device, Diagnostics | 2019 | |
| 2019-05-31 | Novartis Pharmaceuticals Corporation | $250 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | A 52 WEEK OPEN LABEL EVALUATION OF THE EFFECTS OF SACUBITRIL VALSARTAN LCZ696 THERAPY ON BIOMARKERS MYOCARDIAL REMODELIN | 2019 |
| 2019-05-29 | ABBVIE INC. | $17,518 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-05-21 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | M15-570 | 2019 | |
| 2019-05-15 | Abbott Laboratories | $56,386 | Research payment | Cash or cash equivalent | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-05-14 | Kowa Research Institute, Inc. | $66 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2019 |
| 2019-05-09 | Abbott Laboratories | $2,250 | Research payment | Cash or cash equivalent | CardioMEMS Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2019 |
| 2019-05-09 | Regeneron Pharmaceuticals, Inc. | $1,000 | Grant | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | 2019 | |
| 2019-05-09 | Abbott Laboratories | $300 | Research payment | Cash or cash equivalent | CardioMEMS Device, Cardiac Arrhythmias and Heart Failure | CardioMEMS HF System Post Approval Study | 2019 |
| 2019-05-06 | ABBVIE INC. | $17,162 | Research payment | Cash or cash equivalent | M15-566 | 2019 | |
| 2019-05-06 | Abbott Laboratories | $110 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2019 |
| 2019-05-02 | Surmodics, Inc. | $1,998 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-05-02 | Surmodics, Inc. | $1,727 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
The latest 200 records of 292.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Normal, IL, county McLean County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Normal, IL | County McLean County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 53,569 | 171,556 | 12,694,798 |
| Population, 2020 census P1 | 52,736 | 170,954 | 12,812,508 |
| Median age B01002 | 25.0 | 34.3 | 39.0 |
| Under 18 B01001 | 16.1% | 21.2% | 21.8% |
| 65 and over B01001 | 12.1% | 14.6% | 17.0% |
| Households B11001 | 20,387 | 70,220 | 5,036,449 |
| Foreign born B05002 | 8.1% | 7.6% | 14.7% |
| Median household income B19013 | $64,785 | $79,905 | $83,390 |
| Median family income B19113 | $115,492 | $112,292 | $106,018 |
| Per capita income B19301 | $36,168 | $43,372 | $46,406 |
| Poverty rate B17001 | 21.4% | 12.9% | 11.8% |
| Unemployment rate B23025 | 3.9% | 3.1% | 5.8% |
| Civilian labor force B23025 | 28,544 | 90,345 | 6,652,134 |
| Mean commute (minutes) B08013 | 16.5 | 18.3 | 27.8 |
| Bachelor's degree or higher B15003 | 52.9% | 47.2% | 37.8% |
| Housing units B25001 | 22,215 | 75,305 | 5,457,452 |
| Owner-occupied B25003 | 54.8% | 65.1% | 67.1% |
| Renters B25003 | 45.2% | 34.9% | 32.9% |
| Median home value B25077 | $213,600 | $208,400 | $263,300 |
| Median gross rent B25064 | $965 | $1,009 | $1,274 |
| White, not Hispanic B03002 | 75.4% | 76.2% | 58.1% |
| Black B03002 | 10.8% | 8.4% | 13.3% |
| Hispanic or Latino B03002 | 7.2% | 6.4% | 18.8% |
| Asian B03002 | 4.1% | 5.2% | 5.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Normal, IL.
Comments